Innate Pharma S.A. (IPHA) 追踪市盈率为负值 -2.2, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 33.2 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -45.90%, 前瞻盈利收益率 3.01%. PEG 0.18 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 39/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 24.5 | -0.09 | 3.59 | 5.51 | - |
| 2017 | -5.7 | 0.01 | 3.19 | 8.39 | - |
| 2018 | 101.7 | -0.96 | 1.85 | 3.88 | - |
| 2019 | -18.5 | 0.03 | 1.77 | 5.57 | - |
| 2020 | -4.1 | 0.04 | 1.69 | 3.79 | - |
| 2021 | -6.0 | 0.00 | 2.97 | 26.34 | - |
| 2022 | -4.8 | -0.17 | 5.12 | 4.81 | - |
| 2023 | -28.1 | 0.32 | 4.11 | 4.11 | - |
| 2024 | -2.9 | -0.01 | 16.30 | 11.41 | - |
| 2025 | -2.8 | 0.21 | -6.14 | 47.79 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $0.23 | $56.16M | $12.64M | 22.5% |
| 2017 | $-0.89 | $32.63M | $-48.39M | -148.3% |
| 2018 | $0.05 | $79.89M | $3.05M | 3.8% |
| 2019 | $-0.31 | $68.97M | $-20.97M | -30.4% |
| 2020 | $-0.01 | $69.77M | $-63.98M | -91.7% |
| 2021 | $-0.74 | $12.11M | $-59.14M | -488.2% |
| 2022 | $-0.73 | $57.67M | $-58.1M | -100.7% |
| 2023 | $-0.09 | $51.9M | $-7.57M | -14.6% |
| 2024 | $-0.61 | $12.62M | $-49.47M | -392% |
| 2025 | $-0.53 | $2.79M | $-47.24M | -1694.9% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.07 | $-0.08 – $-0.06 | $35.52M | $21.19M – $49.85M | 2 |
| 2027 | $0.17 | $0.13 – $0.20 | $72.84M | $47.22M – $98.47M | 2 |
| 2028 | $-0.65 | $-2.38 – $-0.04 | $30.11M | $8.22M – $92.03M | 1 |
| 2029 | $0.56 | $0.03 – $2.06 | $263.93M | $72.1M – $806.83M | 1 |
| 2030 | $1.80 | $0.10 – $6.60 | $519.71M | $141.97M – $1.59B | 1 |
